




Stroke prevention in atrial fibrillation
comparison of recent international guidelines
Chao, Tze-Fan; Nedeljkovic, Milan A; Lip, Gregory Y H; Potpara, Tatjana S
Published in:
European Heart Journal Supplements







Publisher's PDF, also known as Version of record
Link to publication from Aalborg University
Citation for published version (APA):
Chao, T-F., Nedeljkovic, M. A., Lip, G. Y. H., & Potpara, T. S. (2020). Stroke prevention in atrial fibrillation:
comparison of recent international guidelines. European Heart Journal Supplements, 22(Suppl. O), O53-O60.
https://doi.org/10.1093/eurheartj/suaa180
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
            ? Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
            ? You may not further distribute the material or use it for any profit-making activity or commercial gain
            ? You may freely distribute the URL identifying the publication in the public portal ?
Take down policy
If you believe that this document breaches copyright please contact us at vbn@aub.aau.dk providing details, and we will remove access to
the work immediately and investigate your claim.
Downloaded from vbn.aau.dk on: August 24, 2021
Stroke prevention in atrial fibrillation: comparison of
recent international guidelines
Tze-Fan Chao1,2, Milan A. Nedeljkovic3,4, Gregory Y.H. Lip5,6, and
Tatjana S. Potpara3,4
1Division of Cardiology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan;
2Institute of Clinical Medicine, Cardiovascular Research Center, National Yang-Ming University, Taipei, Taiwan;
3School of Medicine, University of Belgrade, dr Subotica 8, 11000 Belgrade, Serbia;
4Cardiology Clinic, Clinical Centre of Serbia, Visegradska 26, 11000 Belgrade, Serbia;
5Liverpool Centre for Cardiovascular Science, University of Liverpool, Liverpool Heart & Chest Hospital, Liverpool,
UK; and





Stroke prevention is one of the cornerstones of management in patients with atrial
fibrillation (AF). As part of the ABC (Atrial fibrillation Better Care) pathway (A: Avoid
stroke/Anticoagulation; B: Better symptom control; C: Cardiovascular risk and co-
morbidity optimisation), stroke risk assessment and appropriate thromboprophylaxis
is emphasised. Various guidelines have addressed stroke prevention. In this review,
we compared the 2017 APHRS, 2018 ACCP, 2019 ACC/AHA/HRS, and 2020 ESC AF
guidelines regarding the stroke/bleeding risk assessment and recommendations
about the use of OAC. We also aimed to highlight some unique points for each of
those guidelines. All four guidelines recommend the use of the CHA2DS2-VASc score
for stroke risk assessment, and OAC (preferably NOACs in all NOAC-eligible patients)
is recommended for AF patients with a CHA2DS2-VASc score 2 (males) or 3
(females). Guidelines also emphasize the importance of stroke risk reassessments at
periodic intervals (e.g. 4–6months) to inform treatment decisions (e.g. initiation of
OAC in patients no longer at low risk of stroke) and address potentially modifiable
bleeding risk factors.
Introduction
Atrial fibrillation (AF) is associated with an increased risk of
ischaemic stroke, and stroke prevention is a cornerstone in
the management of patients with AF. Oral anticoagulant
therapy (OAC) with vitamin K antagonists (VKA), e.g. warfa-
rin, reduced the risk of AF-associated stroke by 64% com-
pared to placebo.1 Non-VKA antagonist OAC (NOAC),
including dabigatran, rivaroxaban, apixaban, and edoxaban,
further reduced the risk of stroke or systemic embolic events
by 19% compared to warfarin in a pooled analysis of NOACs
pivotal trials.2 The introduction of NOACs has changed the
landscape of stroke prevention and led to a better clinical
outcome in AF patients.3 However, the benefits of stroke risk
reduction with OAC should be carefully balanced against the
risk of bleeding, and optimal stroke prevention strategy for
each patient should be individualized, based on evidence
and shared decision making. International cardiology socie-
ties, such as American College of Cardiology (ACC)/American
Heart Association (AHA)/Heart Rhythm Society (HRS),
American College of Chest Physicians (ACCP), Asia Pacific
Heart Rhythm Society (APHRS), and European Society of
Cardiology (ESC) have published their guidelines or consensus
documents to guide stroke prevention in AF in clinical prac-
tice.4–7 Most recently, the 2020 ESC AF guidelines have been*Corresponding author. Tel: þ38 11 1361 6319, Email: tatjana.pot-
para@med.bg.ac.rs
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published containing updated information about stroke pre-
vention in AF.
In this review, we compared the 2017 APHRS, 2018 ACCP,
2019 ACC/AHA/HRS, and 2020 ESC AF guidelines regarding
the stroke/bleeding risk assessment and recommendations
about the use of OAC, also highlighting some unique points
in each of the guidelines.
Stroke risk assessment
The recommendations concerning stroke risk assessment
are summarized in Table 1. All four guidelines recommend
the use of CHA2DS2-VASc score for stroke risk assessment,
8
with some variations regarding the C (congestive heart fail-
ure) and V (vascular disease) components. In the original
score derivation study,8 ‘C’ refers to congestive heart fail-
ure (HF) or left ventricular (LV) dysfunction. In both ACCP
and ESC guidelines, the ‘C’ was defined as HF with reduced
(HFrEF) or preserved (HFpEF) ejection fraction, and the
2020 ESC guidelines also included hypertrophic cardiomy-
opathy (HCM) based on previous studies showing that the
presence of HCM confers an increased stroke risk and OAC
is beneficial for stroke reduction.9,10 In addition, the ESC
guidelines included angiographically significant coronary
Table 1 Recommended scoring schemes for stroke and bleeding risk assessments












2017 APHRS CHA2DS2-VASc Similar to the original
definitions
— HAS-BLED score
2018 ACCP CHA2DS2-VASc C: Recent decompensated
HF, irrespective of the
ejection fraction or the
presence of moderate-
severe LV systolic im-







CHA2DS2-VASc Similar to the original
definitions
— No specific bleeding score
was recommended
2020 ESC CHA2DS2-VASc C: Clinical HF, or objective
evidence of moderate to
severe LV dysfunction, or
HCM
V: Angiographically signifi-




optimal BP target associ-
ated with the lowest risk
of ischaemic stroke,
death, and other cardio-
vascular outcomes is
120–129/<80mmHg
Age: Age-related risk is a
continuum, but for rea-
sons of simplicity and
practicality, 1 point is
given for age 65–
74 years, and 2 points
for age 75 years
Recent data from Asia sug-
gest that the risk of
stroke may rise from
age 50–55 years upwards
and that a modified
CHA2DS2-VASc score may
be used in Asian
patients
Sc: Female sex is a stroke
risk modifier rather than
a risk factor
HAS-BLED score
ACC/AHA/HRS, American College of Cardiology/American Heart Association/Heart Rhythm Society; ACCP, American College of Chest Physicians;
APHRS, Asia Pacific Heart Rhythm Society; BP, blood pressure; CAD, coronary artery disease; ESC, European Society of Cardiology; HF, heart failure;
LV, left ventricle; PAD, peripheral arterial disease.
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artery disease in the ‘V’ component of the CHA2DS2-VASc
score.11
Importantly, the 2020 ESC AF guidelines highlighted
some aspects concerning the H (hypertension), A (age),
and Sc (female sex) components, emphasizing that the op-
timal blood pressure target associated with the lowest risk
of ischaemic stroke, death, and other cardiovascular out-
comes among patients with AF is 120–129/<80mmHg,12
whereas recent data from Asia suggest that the risk of
stroke may rise from age 50–55 years upwards and that a
modified CHA2DS2-VASc score may be used in Asian
patients.13,14 Female sex is a stroke risk modifier rather
than a risk factor.15 Observational studies showed that
women with no other stroke risk factors (i.e. with a
CHA2DS2-VASc score of 1) have a low stroke risk, similar to
men with a CHA2DS2-VASc score of 0.
16 In the presence of
>1 non-sex stroke risk factor, women with AF consistently
have significantly higher stroke risk thanmen.15 The simpli-
fied CHA2DS2-VA score (without female sex) could guide
the initial decision about OAC in AF patients but not consid-
ering the sex component would underestimate stroke risk
in womenwith AF.17
Bleeding risk assessment
The overview of the bleeding risk assessment tools recom-
mended in specific AF guidelines is shown in Table 1. The
APHRS, ACCP, and ESC AF guidelines all recommend the use
of the HAS-BLED score for bleeding risk assessment, while
the ACC/AHA/HRS did not propose any specific bleeding
risk scheme. The prior 2016 ESC AF guidelines summarized
a list of non-modifiable and modifiable bleeding risk fac-
tors (including some biomarkers, e.g. the growth
differentiation factor-15) and recommended correction of
modifiable bleeding risk factors rather than any formal
scoring.18 However, bleeding risk assessment based solely
on modifiable bleeding risk factors misses important inter-
action between non-modifiable and modifiable risk factors
for bleeding and has been shown to be inferior to a formal
bleeding risk assessment using a bleeding risk score.19,20 Of
note, most of the modifiable bleeding risk factors listed in
the 2016 ESC AF Guidelines are components of the HAS-
BLED score. In the new 2020 ESC AF guidelines, the HAS-
BLED score is recommended to assess bleeding risk: ‘For a
formal risk score-based assessment of bleeding risk, the
HAS-BLED score should be considered to help address modi-
fiable bleeding risk factors, and to identify patients at high
risk of bleeding (HAS-BLED score 3) for early and more
frequent clinical review and follow-up (Class IIa recom-
mendation)’. Most importantly, the estimated bleeding
risk, in the absence of absolute contraindications to OAC,
should not in itself guide treatment decisions to use OAC
for stroke prevention (Class III recommendation).
Recommendations for the use of OAC and
risk re-assessment
Recommendations for the use of OAC for stroke prevention
based on CHA2DS2-VASc score and the risk re-assessment
are summarized in Table 2. All four AF guidelines clearly fa-
vour NOACs over VKAs in all NOAC-eligible patients (i.e.
those without moderate-to-severe mitral stenosis or pros-
thetic mechanical heart valves). The recommendations for
low- and high-risk patients are generally similar in the four
guidelines—OAC is not recommended for patients with a
CHA2DS2-VASc score of 0 (males) or 1 (females), and OAC
Table 2 Recommendations of oral anticoagulants for stroke prevention based on stroke risk and the risk re-assessment
Guidelines Tipping points and the recommendations
for stroke prevention
Statements or recommendations about the risk re-
assessment
2017 APHRS OACs for patients with a score 1 (males)
or 2 (females)
None
2018 ACCP OACs should be offered for patients with a
score 1 (males) or 2 (females)
Stroke risk is dynamic, and risk should be re-assessed
at every patient visit
2019 ACC/AHA/HRS Class IIb recommendation—OACs for score
1 (males) or 2 (females)
Class I recommendation—OACs for score
2 (males) or 3 (females)
Re-evaluation of the need for and choice of anticoag-
ulant therapy at periodic intervals is recommended
to reassess stroke and bleeding risks
2020 ESC Class IIa recommendation—OACs for score
1 (males) or 2 (females)
Class I recommendation—OACs for score
2 (males) or 3 (females)
Class I recommendation—stroke and bleeding risk
reassessment at periodic intervals is recommended
to inform treatment decisions (e.g. initiation of
OAC in patients no longer at low risk of stroke) and
address potentially modifiable bleeding risk
factors.
Class IIa recommendation—in patients with AF initially
at low risk of stroke, first reassessment of stroke
risk should be made 4–6months after the index
evaluation.
ACC/AHA/HRS, American College of Cardiology/American Heart Association/Heart Rhythm Society; ACCP, American College of Chest Physicians;
APHRS, Asia Pacific Heart Rhythm Society; ESC, European Society of Cardiology; OACs, oral anticoagulants.
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use is recommended/indicated in those with a CHA2DS2-
VASc score of2 (males) or3 (females).
A discrepancy among specific guidelines exists for rec-
ommendations about OAC use in patients with a CHA2DS2-
VASc score of 1 (males) or 2 (females). The use of OACs for
stroke prevention in these patients is recommended by the
APHRS and ACCP guidelines and should be considered as
per the ESC guidelines (Class IIa recommendation),
whereas in the 2019 ACC/AHA/HRS guidelines the recom-
mendation is weak (Class IIb). Actually, different risk fac-
tors would carry different weight on stroke risk,21 and age
thresholds for initiating NOACs may even differ for patients
with a different single non-sex stroke risk factor, as follows:
age 35years for HF, 50 years for hypertension or diabetes,
and 55years for vascular disease.22,23 Although no random-
ized control trial has specifically addressed the need for
OAC in patients with a single non-sex CHA2DS2-VASc risk
factor, an overview of subgroup analyses and observational
data suggests that OAC use in such patients confers a posi-
tive net clinical benefit when balancing the reduction in
stroke against the potential for harm with serious bleed-
ing.24–26
An important issue pointed out in the ACCP, ACC/AHA/
HRS and ESC guidelines is the importance of risk-
reassessment (Table 2). The stroke risk in AF patients is not
static as patients become older and may accumulate more
comorbidities over time, which would result in an increase
in the CHA2DS2-VASc score value.
27–29 Among patients with
incident AF who initially had a CHA2DS2-VASc score of 0
(males) or 1 (females) and were not indicated for OAC,
around 16% would have a CHA2DS2-VASc score 1 (males)
or 2 (females) at 1-year follow-up,30 and among such
patients the use of OACs was associated with a lower com-
posite risk of ischaemic stroke, intracranial haemorrhage,
or mortality (adjusted hazard ratio, 0.530).29 Of note, the
HAS-BLED score is also dynamic,31 and therefore, a regular
bleeding risk reassessment is also recommended by the
2020 ESC AF guidelines.
What would be a reasonable time interval at which
stroke risk should be re-assessed in AF patients? Based on
the data from Taiwan, of patients who acquired new stroke
risk factors, 80% would acquire these comorbidities after
4.2months of AF diagnosis. The time period from the ac-
quirement of incident comorbidities to the occurrence of
ischaemic stroke was longer than 4.4months for 90% of
those patients.29 Therefore, the ESC guidelines recom-
mend that in patients with AF initially at low risk of stroke,
first reassessment of stroke risk should bemade 4–6months
after the index evaluation (Class IIa).
Peri-cardioversion and peri-catheter
ablation
The key concepts and recommendations for stroke risk
management peri-cardioversion are generally similar be-
tween the 2019 ACC/AHA/HRS and 2020 ESC AF guidelines,
except for some differences regarding the duration of the
AF episode before cardioversion. The ESC guidelines rec-
ommend that in all patients with AF duration of >24h un-
dergoing cardioversion, therapeutic anticoagulation should
be continued for at least 4weeks even after successful car-
dioversion to sinus rhythm (beyond 4weeks, the decision
about long-term OAC treatment is determined by the pres-
ence of stroke risk factors) (class IIa), while the ACC/AHA/
HRS guidelines set the AF duration threshold at 48 h.
Also, in patients with a CHA2DS2-VASc of 0 in men or 1 in
women, post-cardioversion anticoagulation for 4weeks
may be omitted for those with a definite duration of AF
24h (ESC guidelines, Class IIb) or <48h (ACC/AHA/HRS
guidelines, Class IIb).
There are two new recommendations for stroke risk
management peri-catheter ablation in the 2020 ESC AF
guidelines—(i) in AF patients with stroke risk factors not
taking OAC before ablation, it is recommended that pre-
procedural management of stroke risk includes initiation of
anticoagulation and, preferably, therapeutic OAC for at
least 3weeks before ablation (Class I), or alternatively, the
use of transoesophageal echocardiography to exclude LA
thrombus before ablation (Class IIa); and (ii) For patients
undergoing AF catheter ablation who have been therapeu-
tically anticoagulated with warfarin, dabigatran, rivaroxa-
ban, apixaban, or edoxaban, performance of the ablation
procedure without OAC interruption is recommended
(Class I). While not interrupting NOACs peri-catheter abla-
tion is favoured in all AF guidelines, the 2020 ESC AF guide-
lines clearly defined the term ‘uninterrupted’. Although
this term is frequently used in clinical practice for the de-
scription of regimens where one or two NOAC doses are
omitted before ablation, NOAC administration before abla-
tion was truly uninterrupted in the randomized controlled
trials comparing uninterrupted NOACs vs. warfarin.
Therefore, the 2020 ESC AF guidelines stated that there is
no reason to recommend omitting one or two NOAC doses
before ablation, as the administration of the first dose the
evening after ablation or the next morning (if this corre-
sponds to the timing of the next dose according to the
patient’s previous OAC regimen) appeared to be safe.
Specific conditions with challenging
treatment decision-making
There are several specific conditions such as advanced
chronic kidney disease (CKD), advanced liver disease/liver
cirrhosis, and atrial high rate episodes (AHRE) where high-
quality evidence is lacking and treatment decision-making
for the prevention of AF-related strokemay be challenging.
The specific guideline recommendations/statements refer-
ring to these scenarios are summarized in Table 3.
Patients with AF and stage IV (CrCl 15–29mL/min) CKD or
end-stage renal disease [ESRD; creatine clearance (CrCl)
<15mL/min or on dialysis] are at increased risk for both
stroke and bleeding. There is no high-quality randomized
trial-based evidence informing the use of VKAs or NOACs
compared to non-OAC in this population (the RENAL-AF
trial (NCT02942407) of apixaban vs. warfarin in patients
with AF on haemodialysis was stopped prematurely and
was inconclusive regarding relative stroke and bleeding
rates). Therefore, most of the recommendations regarding
the use of VKAs or NOACs in these patients (where pro-
vided) are based on pharmacokinetic data or observational
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Table 3 Recommendations/statements of stroke prevention in special scenarios and left atrial appendage occlusion
Guidelines Advanced CKD Advanced liver disease/
liver cirrhosis
AHREs LAAO
2017 APHRS • In patients with ESRD or




(TTR > 70%) might be
useful, the data are
lacking
— — • Interventional percutane-
ous LAA closure with the
WATCHMAN device may be
considered in patients with
non-valvular AF who have
high risk of stroke, but ma-
jor contraindications to
OAC therapy
• Surgical excision of the LAA
may be considered in
patients undergoing con-
comitant cardiac surgery
2018 ACCP • In stage IV (CrCl 15–
30mL/min) CKD, sug-
gesting using VKAs and
selected NOACs [rivarox-
aban 15mg QD, apixaban
2.5mg bid, edoxaban
30mg QD, and (in USA
only) dabigatran 75mg
bid] with caution, based
on pharmacokinetic data
• In end-stage renal dis-
ease (CrCl < 15mL/min
or dialysis-dependent),
suggesting using well-
managed VKA with TTR
>65–70%





there is abnormal clot-
ting tests, such patients
may be at higher risk of
bleeding on VKA, possi-





• In patients with AF, pre-
scription of OACs could
be considered as a result
of an individualized clin-
ical assessment taking
into account overall
AHRE burden (in the
range of hours rather
than minutes) and spe-
cifically, the presence of
AHRE >24 h, individual
stroke risk (using
CHA2DS2-VASc), pre-
dicted risk benefit of




• In patients with AF at high
risk of ischaemic stroke
who have absolute contra-
indications for OAC, sug-
gesting using LAA occlusion
(Weak recommendation,
low quality evidence)
• In AF patients at risk of
ischaemic stroke undergo-
ing cardiac surgery, we sug-
gest surgical exclusion of
the LAA for stroke preven-
tion, but the need for long-





• Class IIb - For patients
with AF who have a
CHA2DS2-VASc score of 2
or greater in men or 3 or
greater in women and
who have ESRD (CKD;
CrCl <15mL/min) or are
on dialysis, it might be
reasonable to prescribe
warfarin (INR 2.0 to 3.0)
or apixaban for oral
anticoagulation
– • Prospective clinical tri-
als of prophylactic anti-
coagulation based on
device-detected AF are
under way but have not
been completed
• Although increased dura-
tion of AHREs is associ-
ated with increased
stroke risk, the thresh-
old duration of AHREs
that warrants anticoagu-
lation is unclear
• Current approaches fac-
tor in the duration of de-
vice-detected AF and
the patient’s stroke risk
profile, bleeding risk, an
preferences to deter-
mine whether to initiate
long-term
anticoagulation
• Class IIb - Percutaneous LAA
occlusion may be consid-
ered in patients with AF at




2020 ESC • In patients with CrCl 15–
29mL/min, RCT-derived
data on the effect of
VKA or NOACs are
lacking
• Patients with hepatic
dysfunction were gener-
ally excluded from the
RCTs
• Despite the paucity of
data, observational




clinical AF (24 h) and
an estimated high
• Class IIb - LAA occlusion
may be considered for
stroke prevention in
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studies. Generally, if a VKA is prescribed, a high time in
therapeutic range (TTR > 70%) is crucial for its optimal ef-
fect. For stage IV (CrCl 15–29mL/min) CKD, the ACCP
guidelines suggest the use of VKAs or selected NOACs [rivar-
oxaban 15mg once daily, apixaban 2.5mg twice daily,
edoxaban 30mg once daily or (in USA only) dabigatran
75mg bid] with caution, based on pharmacokinetic data.
For ESRD patients (CrCl < 15mL/min or on dialysis) having
a CHA2DS2-VASc score 2 (males) or 3 (females), the
ACC/AHA/HRS guidelines stated that it might be reason-
able to prescribe warfarin [international normalized ratio
(INR) 2.0–3.0] or apixaban for oral anticoagulation (Class
IIb). Differently, there was no formal recommendation for
ESRD patients in the ESC guidelines which only mentioned
that the evidence for the benefit of OAC in patients with
end-stage kidney disease with CrCl <15mL/min or on dial-
ysis is limited, and to some extent controversial. Further
high-quality randomized trials are necessary to inform us
how tomanage these patients.
Data about the use of OACs among AF patients with ad-
vanced liver cirrhosis are very limited,32 and such patients
were not included in pivotal NOACs trials on stroke preven-
tion in AF. There are no formal recommendations in the
four guidelines for this scenario, with some statements pro-
vided in the ACCP and 2020 ESC AF guidelines (Table 3).
Importantly, all NOACs are contraindicated in patients
within Child-Turcotte-Pugh C hepatic dysfunction, and
rivaroxaban is not recommended for patients in the Child-
Turcotte-Pugh B or C category.
The use of NOACs for stroke prevention in patients with
AHRE is tested in two ongoing trials, the ARTESiA (Apixaban
for the Reduction of Thrombo-Embolism in Patients With
Device-Detected Sub-Clinical Atrial Fibrillation; NCT
01938248) and NOAH (Non-vitamin K Antagonist Oral
Anticoagulants in Patients With Atrial High Rate Episodes;
NCT 02618577) trial. Previously, the ASSERT trial showed
that the presence of AHRE (atrial rate >190 b.p.m. for
more than 6min) was associated with a higher risk of
ischaemic stroke or systemic embolism (hazard ratio,
2.49).33 Further analysis of the ASSERT trial demonstrated
that the increased risk of ischaemic stroke or systemic em-
bolism was only observed for patients with the longest epi-
sode of AHRE >24 h.34 Therefore, the 2020 ESC AF
guidelines suggest that OACs may be considered in selected
patients with longer duration of AHRE/subclinical AF
(24h) and an estimated high individual risk of stroke,
accounting for the anticipated net clinical benefit and
informed patient’s preference.
Left atrial appendage occlusion
There are no high-quality, large-scale randomized trials
comparing the efficacy and safety of NOACs and left atrial
appendage occlusion (LAAO) for stroke prevention in AF,
and in all four AF guidelines, LAAO is recommended as a
second-line treatment for stroke prevention. For example,
the 2020 ESC AF guidelines recommend that LAA occlusion
may be considered for stroke prevention in patients with
AF and contraindications for long-term anticoagulant
treatment (Class IIb). Also, surgical occlusion or exclusion
of the LAA may be considered for stroke prevention in
patients with AF undergoing cardiac surgery (Class IIb).
Conclusions
All four guidelines suggest the use of the CHA2DS2-VASc
score for stroke risk assessment, and OAC (preferably
NOACs in all NOAC-eligible patients) is recommended for
AF patients with a CHA2DS2-VASc score 2 (males) or 3
(females). Three of the four guidelines (except for
ACC/AHA/HRS guidelines) suggest that OAC should be con-
sidered for patients with a CHA2DS2-VASc score of 1 (males)
or 2 (females). Guidelines also emphasize the
importance of risk reassessments at periodic intervals (e.g.
4–6months for stroke risk by ESC guidelines) to inform
treatment decisions (e.g. initiation of OAC in patients no
Table 3 Continued
Guidelines Advanced CKD Advanced liver disease/
liver cirrhosis
AHREs LAAO
• The evidence for the
benefits of OAC in
patients with end-stage
kidney disease with
CrCl 15mL/min or on
dialysis is even more lim-
ited, and to some extent
controversial
studies did not raise con-
cerns regarding the use
of NOACs in advanced
hepatic disease
• NOACs are contraindi-
cated in patients within
Child-Turcotte-Pugh C
hepatic dysfunction, and
rivaroxaban is not rec-
ommended for patients
in the Child-Turcotte-
Pugh B or C category
individual risk of stroke,
accounting for the antic-
ipated net clinical bene-
fit and informed
patient’s preferences
• Class IIb - Surgical occlusion
or exclusion of the LAA may
be considered for stroke
prevention in patients with
AF undergoing cardiac
surgery
ACC/AHA/HRS, American College of Cardiology/American Heart Association/Heart Rhythm Society; ACCP, American College of Chest Physicians;
AF, atrial fibrillation; AHRE, atrial high rate episode; APHRS, Asia Pacific Heart Rhythm Society; CKD, chronic kidney disease; CrCl, creatinine clear-
ance; ESC, European Society of Cardiology; ESRD, end-stage renal disease; INR, international normalized ratio; LAAO, left atrial appendage occlusion;
NOACs, non-vitamin K antagonist oral anticoagulants; OACs, oral anticoagulants; RCTs, randomized controlled trials; TTR, time in therapeutic range;
VKA, vitamin K antagonist.
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longer at low risk of stroke) and address potentially modifi-
able bleeding risk factors. Further studies are necessary to
guide clinical practice in some special/difficult scenarios.
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